BIOS — Biosenic SA Share News
0.000.00%
Last trade - 00:00Brief: Bone Therapeutics Expects Topline Results In Knee Osteoarthritis Study In Q3 2021
Brief: Bone Therapeutics Announces Closing Of Private Placement
Brief: Bone Therapeutics Prices About EUR 10 Mln Private Placement
Brief: Bone Therapeutics Announce Start Of New Research Collaboration
Brief: Bone Therapeutics Eyes EUR 15-16 Mln FY Net Cash Burn
Brief: Bone Therapeutics And Catalent Sign Agreements To Streamline ALLOB Production
Brief: Bone Therapeutics Reaches 50% Treated Patients In JTA-004 Phase III Study
Brief: Bone Therapeutics' Allob Phase IIA Study Results Positive
Brief: Bone Therapeutics To Develop And Commercialize ALLOB With Link Health And Pregene
Brief: Bone Therapeutics H1 Operating Income Down At 1.04 Million Euros
Brief: Bone Therapeutics Has Received Eur 0.6 Million In Grants From Walloon Region
Brief: Bone Therapeutics Gets EUR 1.0 Mln To Advance JTA-004 Phase III Knee Osteoarthritis Study
Brief: Bone Therapeutics Treats First Patients In Pivotal JTA-004 Phase III Study
Brief: Bone Therapeutics Raises Additional EUR 4 Mln In Bonds
Brief: Bone Therapeutics: Sufficient Cash To Carry Out Objectives Into Q1 2021
Brief: Bone Therapeutics Secures 11 Million Euro Financing
Brief: Bone Therapeutics Receives Clinical Trial Application Approval For Two Studies
Brief: Bone Therapeutics Says Cash Burn For FY 2019 Is Below Guidance
Brief: Bone Therapeutics Says It Submitted Clinical Trial Application For Pivotal JTA-004 Phase III study